e8vk
 

 
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of earliest event reported):
  March 14, 2005
   

Introgen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)
         
Delaware   0-21291   74-2704230
 
(State or other jurisdiction
of incorporation) 		  (Commission
File Number) 		  (IRS Employer
Identification No.)
     
301 Congress Avenue, Suite 1850, Austin, Texas   78701
 
(Address of principal executive offices)   (Zip Code)
     
Registrant’s telephone number, including area code:
  (512) 708-9310
   

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

 

Item 2.02. Results of Operations and Financial Condition.

      On March 14, 2005, Introgen Therapeutics, Inc. issued its press release announcing financial results for the three and twelve months ended December 31, 2004. A copy of this press release is attached hereto as Exhibit 99.1.

      The information in this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

Item 9.01. Financial Statements and Exhibits.

  (c)   Exhibits.
     
99.1
  Press Release dated March 14, 2005.

-2-

 

SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
Dated: March 14, 2005  INTROGEN THERAPEUTICS, INC.
 		  
  By:   /s/ JAMES W. ALBRECHT, JR.    
    James W. Albrecht, Jr.   
    Chief Financial Officer   
 

-3-

 

INDEX TO EXHIBITS

     
Exhibit    
Number   Description of Document
99.1
  Press Release dated March 14, 2005.